HK Stock Market Move | KEYMED BIO-B(02162) rose more than 4% after the addition of Sipuzhibain injection into the national basic medical insurance drug list.

KEYMED BIO-B(02162) opened more than 4% higher, and as of the time of writing, it has risen by 4.23% to HK$61.6, with a turnover of HK$1.3244 million. On the news front, on December 7th, Kangnora announced that its independently developed Class 1 new drug Kangyueda (Dupilumab injection) has been included in the "National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalogue (2025)" ("National Basic Medical Insurance Drug Catalogue"), which will officially be implemented from January 1, 2026. It is reported that Kangyueda (Dupilumab) is the first domestically developed and approved IL-4R humanized monoclonal antibody, which precisely inhibits the progression of type 2 inflammatory diseases by dual blocking of the IL-4/IL-13 signaling pathway. Kangyueda (Dupilumab) has currently been approved for 3 indications: moderate to severe atopic dermatitis in adults with inadequate control or unsuitable for topical therapy, chronic sinusitis with nasal polyps uncontrolled by glucocorticoid therapy and/or surgical treatment, and moderate to severe seasonal allergic rhinitis in adults with inadequate symptom control after treatment with intranasal glucocorticoids and antihistamines. All 3 indications have been included in the new version of the National Basic Medical Insurance Drug Catalogue.